Open Access
Review
Table 1
A summary of schistosome products with immunomodulatory effect against autoimmune diseases.
Schistosome product | Diseases | Immunomodulatory effect | References | |
---|---|---|---|---|
Egg | Soluble egg antigen (SEA) | Graves hyperthyroidism | Suppresses Th1-type anti-TSHR IgG2a autoantibodies and IFN-γ secretion | [88] |
Asthma | Downregulates Th2 response and upregulates Th1 response, increases IFN-γ production | [97] | ||
Type 1 and Type 2 Diabetes | Induces Th2 response | [115] | ||
Stimulates IL-33 secretion and increases Tregs | [48] | |||
Inflammatory bowel diseases | Increases FoxP3+ Treg cells and secrets Th2 cytokines | [49] | ||
Skin transplantation | Increases CD4+IL-4+ T cells and CD4+Foxp3+ T cells but decreases CD4+IFN-γ+ T cells in the skin transplant | [59] | ||
Autoimmune encephalomyelitis | Induces Th2-dominant response and reduces leukocyte infiltration in the CNS | [20] | ||
Interleukin-4 inducing principle from Schistosoma mansoni eggs (IPSE/alpha-1) | Allergic airway inflammation | Induces Bregs which activates Tregs | [65] | |
28-kilodalton glutathione S-transferases (28GST) | Schistosomiasis | Induces Th1 response | [67] | |
Colitis | Downregulates Th1 and Th17 and activates M2 macrophages and Th2 responses | [106] | ||
Schistosoma japonicum HSP60-derived peptide (SJMHE) | Delayed-type hypersensitivity | Induces CD4+CD25+ Tregs with overexpression of CTLA-4, IL-10, and TGF-β1 | [121] | |
Inflammatory bowel diseases | Increases Th2 and Treg cells, upregulates IL-10 and reduces Th17 and IL-17 | [108] | ||
Allergic rhinitis | Upregulates Bregs with IL-10 production | [42] | ||
Schistosoma mansoni 14-kDa fatty acid-binding protein (Sm14) | Schistosomiasis | Activates CD4+ T lymphocytes and produces higher IFN-γ and TNF-α | [8] | |
Increases production of IgG specific antibodies, IL-2, TNF-α, and IFN-γ | [104] | |||
Omega-1 (ω1) | Diabetes | Regulates an inflammasome-dependent IL-1β and triggers Tregs production | [55] | |
Human immunodeficiency virus infection | Induces CD4+ T cells and stimulates Th2 responses | [86] | ||
Schistosoma mansoni major egg antigen (Sm-p40) | Hypertension | Reduces Caveolin-1 expression by stimulating TLR-4/CD14-mediated phosphorylation | [75] | |
Cercariae | Cercarial antigen | Arthritis | Increases serum levels of IL-10 and IFN-γ; increases Tregs and reduces IL-17 | [35] |
Colitis | Induces macrophage-dependent response | [112] | ||
KS-84 (a synthetic peptide of Sm16) | Liver fibrosis | Downregulates TGF-β expression | [16] | |
Schistosoma mansoni Cathepsin B 1 (SmCB1) | Schistosomiasis | Increases production of IL-5 and IL-13 and decreases IFN-γ secretion | [114] | |
Adult worm | Schistosoma mansoni Kunitz type serine protease inhibitor (SmKI-1) | Acetaminophen-induced liver injury | Reduces neutrophil recruitment and elastase activity | [83] |
Pleural cavity inflammation | Lowers leukocyte infiltration | [83] | ||
Schistosoma mansoni protein 29 (Sm29) | Leishmaniasis | Increases CD4+CD25 and CD4+CTLA-4+ T cells and increases IL-10 | [71] | |
Allergic airway inflammation | Decreases IgE levels and increases the numbers of CD4+FoxP3+ T cells | [15] | ||
Human T cell lymphocytic virus type 1 | Induces IL-10 and reduces IFN-γ | [69] | ||
Schistosoma japonicum tetraspanin orphan receptor (SjTOR) | Schistosomiasis | Modulates complement pathway; induces IgG1 and IgG2a antibodies | [73] |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.